By promoting hospitals in the country to join PNEx, Eugen, which works together with the Government in Uruguay and leading local sites to increase the flow of clinical trials to Latin America, (and Uruguay in particular) will support Clinerion’s expansion into the region. It will use PNEx to provide clients with solid real patient health data insights when choosing the geographic distribution of its clinical trials, better trial design tools and effective patient enrolment. Hospitals in Uruguay will increase their visibility and be in a better position to attract global multicentric trials while providing patients with innovative treatments.
The latest development marks another advancement in Uruguay’s healthcare system – where the country previously made headlines with its pioneering medical and recreative cannabis regulation.
“Our partnership with Clinerion couldn’t be timelier, as Uruguay has gradually shifted its economic model to transform itself into a centre of innovation in Latin America,” said Claudia Rodriguez Verde, Director of Operations at Eugen. “Clinerion’s PNEx is already reshaping drug development worldwide and brings to Uruguay and Latin America the new models of clinical trials that use data and artificial intelligence. We are very enthusiastic about this partnership and we are certain it will leverage Uruguay’s efforts to be at the forefront of clinical research, as well as being a meaningful step to provide Eugen’s customers with precise data generated in real time.”